Haemodilution for major vascular surgery--using 3.5% polygeline (Haemaccel)

Area of Science:

• Cardiovascular Surgery
• Anesthesiology
• Transfusion Medicine

Background:

• Major vascular surgery is associated with significant blood loss.
• Homologous blood transfusions carry inherent risks.
• Alternative strategies to minimize allogeneic blood use are crucial.

Purpose of the Study:

• To evaluate the efficacy and safety of intra-operative haemodilution and autotransfusion in major vascular surgery.
• To compare blood transfusion requirements between patients undergoing haemodilution and those who did not.
• To assess the safety profile of Polygeline (haemaccel) as a diluent.

Main Methods:

• Prospective comparison of two groups of patients undergoing major vascular surgery.
• Group 1: 32 patients underwent intra-operative haemodilution and autotransfusion using Polygeline.
• Group 2: 25 patients served as controls, with haemodilution contraindicated.

Main Results:

• Mean intra-operative blood loss was similar between groups.
• Haemodiluted patients required significantly fewer homologous blood units (2.6 units) compared to non-diluted patients (6.0 units).
• No mortality or procedure-attributed morbidity was observed in the haemodiluted group.

Conclusions:

• Intra-operative haemodilution is an effective and safe method to reduce homologous blood transfusion requirements in major vascular surgery.
• Polygeline (haemaccel) is a suitable diluent for this procedure.
• This technique offers a significant benefit in managing blood replacement during complex vascular operations.